The present invention relates to a tableted chewing gum composition for oral administration of cannabinoids, the composition comprising water-soluble chewing gum ingredients and water-insoluble gum base located in a plurality of particles, wherein a first population of particles comprises water-insoluble gum base, including one or more polyvinyl acetate elastomer plasticizers, and a second population of particles comprises water-soluble chewing gum ingredients, the second population of particles being free of water-insoluble gum base, wherein the chewing gum composition comprises one or more cannabinoids.

An oral product includes a body that is wholly receivable in an oral cavity. The body includes a polymer matrix and one or more flavorants and/or active ingredients embedded in the polymer matrix. The polymer matrix can include a copolymer of ethylene and one or more vinyl monomers or zein. For example, the polymer can be ethylene-vinyl acetate copolymer and/or ethylene-vinyl alcohol copolymer. In some cases, the oral product can include tobacco and/or nicotine.

The present invention relates to a multiparticulate solid dosage form (1) which has an elastic texture and which contains a plurality of microcapsules (2) having a core (2a) and a shell (2b) that are embedded in an edible matrix (3). Microcapsules (2) contain an active ingredient which may be a pharmaceutical drug and/or a micronutrient. The multiparticulate solid dosage form of the invention is obtainable by a method wherein a mixture comprising water, microcapsules and starch particles is casted. The starch particles swell or dissolve only after casting.

The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

A composition containing cashew leaf extract comprises at least cashew leaf extract, magnesium stearate and maltodextrin wherein the said cashew leaf extract is extracted by water or alcohol or the combination of alcohol and water or other organic solvents or combination thereof, preferably the hydroalcoholic extracts. The composition containing cashew leaf extract can be used as the tonic and/or adaptogenic agents, for enhancing the efficiency of male sexual functions, for enhancing male sexual fertility, for improving cognitive functions. The composition containing cashew leaf extract according to this invention is aimed to increase the commercialization value of cashew leaf which is rich of the health benefit from several nutrient contained in the cashew leaf such as increasing the function of neurological system related to monoamines especially dopamine which increase male sexual functions and also improving the cognitive function.

The invention relates to an oral tablet for taste masking of active ingredients, the tablet comprising a population of particles and an active ingredient with off-note taste, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting at least partly in induced taste masking of the active ingredient upon mastication of the tablet.

A composition containing one or more materials selected from the group consisting of fatty acids, proteins, peptides, amino acids, vitamins, minerals, alcohols, sweeteners, acidulants, antioxidants, thickening stabilizer, and surfactants, and a flavonoid-cyclodextrin inclusion compound, wherein the inclusion compound contains an inclusion compound obtained by treating a flavonoid having a rhamnoside structure with an enzyme having rhamnosidase activity in the presence of a cyclodextrin. According to the present invention, the bitterness and the changes in color tones originated from flavonoids can be inhibited, and foodstuff or the like having an unpleasant taste can be improved, so that the present invention can be suitably utilized in fields such as medicaments, foodstuff, health foods, foods for specified health use, and cosmetics.

The invention relates to a solid pharmaceutical tablet for oral delivery, the tablet comprising calcium carbonate in an amount of more than 30% by weight of the tablet and organic water-insoluble components in an amount of more than 20% by weight of the tablet, wherein the tablet is designed to be masticated into a coherent residual containing the organic water-insoluble components, and wherein the tablet is adapted to release more than 80% of the calcium carbonate within 5 minutes of mastication.

One or more synergistic nutraceutical chewable formulations providing enhanced thermogenesis leading to enhanced/improved mental concentration and stamina while minimizing adrenaline and dopamine withdrawal. The primary ingredients comprising caffeine, hordenine, and -phenylethylamine, which are delivered in a chewable form, such as chewing gum, for release and consumption.

The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.